Alunno Alessia, Leone Maria Comasia, Giacomelli Roberto, Gerli Roberto, Carubbi Francesco
Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy.
Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Front Med (Lausanne). 2018 Apr 13;5:102. doi: 10.3389/fmed.2018.00102. eCollection 2018.
Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease mainly affecting exocrine glands and leading to impaired secretory function. The clinical picture is dominated by signs and symptoms of mucosal dryness and the course of the disease is mild and indolent in the majority of cases. However, a subgroup of patients can also experience extraglandular manifestations that worsen the disease prognosis. pSS patients are consistently found to have a higher risk of developing non-Hodgkin lymphoma (NHL) compared with patients with other autimmune disorders and to the general population. NHL is the most severe comorbidity that can occur in pSS, therefore recent research has aimed to identify reliable clinical, serological, and histological biomarkers able to predict NHL development in these subjects. This review article encompasses the body of evidence published so far in this field highlighting the challenges and pitfalls of different biomarkers within clinical practice. We also provide an overview of epidemiological data, diagnostic procedures, and evidence-based treatment strategies for NHL in pSS.
原发性干燥综合征(pSS)是一种主要影响外分泌腺并导致分泌功能受损的系统性自身免疫性疾病。临床表现主要为黏膜干燥的体征和症状,在大多数情况下,疾病进程轻微且进展缓慢。然而,一部分患者也会出现腺体外表现,这会使疾病预后恶化。与其他自身免疫性疾病患者及一般人群相比,pSS患者患非霍奇金淋巴瘤(NHL)的风险持续较高。NHL是pSS可能发生的最严重合并症,因此,最近的研究旨在确定能够预测这些患者发生NHL的可靠临床、血清学和组织学生物标志物。这篇综述文章涵盖了该领域迄今为止发表的证据,突出了不同生物标志物在临床实践中的挑战和缺陷。我们还概述了pSS中NHL的流行病学数据、诊断程序和循证治疗策略。